- Home
- CAL vs GYRE Comparison
CAL vs GYRE Comparison
Compare CAL & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAL
- GYRE
- Stock Information
- Founded
- CAL 1878
- GYRE 2002
- Country
- CAL United States
- GYRE United States
- Employees
- CAL N/A
- GYRE N/A
- Industry
- CAL Shoe Manufacturing
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- CAL Consumer Discretionary
- GYRE Health Care
- Exchange
- CAL Nasdaq
- GYRE Nasdaq
- Market Cap
- CAL 1.5B
- GYRE 1.2B
- IPO Year
- CAL N/A
- GYRE N/A
- Fundamental
- Price
- CAL $38.80
- GYRE $12.50
- Analyst Decision
- CAL Hold
- GYRE
- Analyst Count
- CAL 2
- GYRE 0
- Target Price
- CAL $40.00
- GYRE N/A
- AVG Volume (30 Days)
- CAL 494.2K
- GYRE 43.7K
- Earning Date
- CAL 09-12-2024
- GYRE 08-13-2024
- Dividend Yield
- CAL 0.72%
- GYRE N/A
- EPS Growth
- CAL 3.18
- GYRE N/A
- EPS
- CAL 4.71
- GYRE N/A
- Revenue
- CAL $2,813,758,000.00
- GYRE $111,587,000.00
- Revenue This Year
- CAL $2.05
- GYRE $25.32
- Revenue Next Year
- CAL $3.93
- GYRE $12.95
- P/E Ratio
- CAL $8.23
- GYRE N/A
- Revenue Growth
- CAL N/A
- GYRE N/A
- 52 Week Low
- CAL $24.71
- GYRE $4.80
- 52 Week High
- CAL $44.51
- GYRE $30.40
- Technical
- Relative Strength Index (RSI)
- CAL 45.81
- GYRE 50.86
- Support Level
- CAL $39.16
- GYRE $11.38
- Resistance Level
- CAL $40.71
- GYRE $13.90
- Average True Range (ATR)
- CAL 1.30
- GYRE 1.20
- MACD
- CAL -0.58
- GYRE 0.05
- Stochastic Oscillator
- CAL 2.39
- GYRE 39.51
About CAL Caleres Inc.
Caleres Inc is a footwear retailer in the United States. The Company's business are organized into two reportable segments are famous Footwear and Brand Portfolio. The famous Footwear segment is comprised of famous Footwear retail stores, famousfootwear.com and famousfootwear.ca. The Brand Portfolio segment offers retailers and consumers a carefully cultivated portfolio of top brands. This segment is comprised of wholesale operations that designs, develops, sources, manufactures, markets and distributes branded, licensed and private-label footwear to online retailers, national chains, department stores, mass merchandisers and independent retailers, as well as Company owned famous Footwear, Sam Edelman, Naturalizer and Allen Edmonds stores and e-commerce businesses.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.